

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities and neither this announcement nor anything herein forms the basis for any contract or commitment whatsoever. Neither this announcement nor any copy hereof may be taken into or distributed in the United States.

The information contained in this announcement is not for distribution, directly or indirectly, in or into the United States. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Shares and the Bonds mentioned herein have not been, and will not be, registered under the Securities Act, and may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the Securities Act. No public offering of the Shares or the Bonds will be made in the United States.



The United Laboratories International Holdings Limited **聯邦制藥國際控股有限公司**

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

U.S.\$130,000,000 CONVERTIBLE BONDS DUE 2021

RESET OF THE CONVERSION PRICE OF THE BONDS

Lead Manager

CREDIT SUISSE 

Reference is made to the announcements of the Company dated 21 November 2016 and 5 December 2016 (the “**Announcements**”). Unless otherwise defined, all capitalised terms used in this announcement shall have the same meaning as defined in the Announcements.

In accordance with Condition 6(E) of the Terms and Conditions, if the Reset Reference Price for the period of 15 consecutive Trading Days immediately prior to and excluding 13 December 2016 (the “**Reset Date**”), converted into US Dollars at the average of the daily Prevailing Rate (as defined in the Terms and Conditions) for the period of 15 consecutive Trading Days immediately prior to and excluding the Reset Date, is less than U.S.\$0.6008, being the Closing Price on 21 November 2016 converted into US Dollars at the Fixed Exchange Rate, the Conversion Price shall be adjusted on a one-time basis on the Reset Date provided that, *inter alia*, any such adjustment to the Conversion Price shall be limited such that the adjusted Conversion Price in no event shall be less than 75% of the Conversion Price prevailing on the Issue Date.

The Reset Reference Price, after computation and converted into US Dollars at the average of the daily Prevailing Rate, is U.S.\$0.5443 per Share, which is less than U.S.\$0.6008, being the Closing Price on 21 November 2016 converted into US Dollars at the fixed Exchange Rate. The Conversion Price has therefore been adjusted, in accordance with Condition 6(E) of the Terms and Conditions, to HK\$4.86 per Share (the “**Adjusted Conversion Price**”) with effect from the Reset Date.

In the event that the Bonds are fully converted at the Adjusted Conversion Price, an aggregate of 207,473,045 Shares will be issued by the Company, representing approximately 12.75% of the issued ordinary share capital of the Company and approximately 11.31% of the issued ordinary share capital of the Company, as enlarged.

By order of the Board of
The United Laboratories International Holdings Limited
Leung Wing Hon
Company Secretary

Hong Kong, 13 December 2016

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Mr. Huang Bao Guang, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.